Cells lacking B2M surface expression and methods for allogeneic administration of such cells
AssigneePresident and Fellows of Harvard College
InventorsChad A. Cowan, Leonardo M. R. Ferreira, Torsten B. Meissner, Jack L Strominger
Life of this patent
Estimating the term…
Abstract
Disclosed herein are cells and populations of cells comprising a genome in which the B2M gene has been edited to eliminate surface expression of MHC Class I protein in the cells or population of cells, and methods for allogeneic administration of such cells to reduce the likelihood that the cells will trigger a host immune response when the cells are administered to a subject in need of such cells.
Claims8
An isolated primary human cell or population of primary human cells comprising a genome in which the β2-microglobulin (B2M) gene on chromosome 15 has been edited to delete a contiguous stretch of genomic DNA consisting of the nucleotide sequence as set forth in SEQ ID NO:
- 1, wherein the contiguous stretch of genomic DNA is deleted between a first human B2M gene target site complementary to a nucleotide sequence consisting of SEQ ID NO:
- 16 and a second human B2M gene target site complementary to a nucleotide sequence consisting of SEQ ID NO:
- 21, wherein the isolated primary human cell or population of primary human cells are selected from the group consisting of a T cell and a CD34+ cell, thereby eliminating surface expression of MHC Class I molecules in the cell or population of cells.
Dependencies are inferred from the claim text.